0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Beads > VEGF165 > MBS-K036

Human VEGF165-coupled Magnetic Beads

Order Now

ItemsSize (2mg)Size(5mg X 2)
Particle size2 μm2 μm
Physical appearancePowder mixturePowder mixture
Amount of Coupled Protein≈1414 pmol (31.6 μg) VEGF165/mg Beads≈1414 pmol (31.6 μg) VEGF165/mg Beads
Binding Capacity>137 pmol (20μg) Anti-VEGF antibody/mg beads>137 pmol (20 μg) Anti-VEGF antibody/mg beads
FormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% Trehalose
Reconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)
  • Background
    The Human VEGF165-coupled Magnetic Beads is produced by coupling biotinylated human VEGF165 protein to streptavidin-conjugated magnetic beads. The pre-coupled beads are ready to use for capturing anti-VEGF165 antibody or VEGFR2/KDR protein from your sample with high specificity. The uniform size and large surface-to-volume ratio of the beads ensure highly efficent immunocapture in a simple, fast and convenient workflow with high reproducibilty of data.
  • Source
    Human VEGF165 Protein is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191(Accession # P15692-4).
  • Application
    This product is intended for immunocapture, biopanning and flow cytometry. This is a non-sterile product.
    *The Isotype control (Cat. No. SMB-B01) is sold separately.
  • Reconstitution

    See Certificate of Analysis (CoA) for detailed instruction.

  • Storage
    Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C.Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
  • Assay Principles
    Antibody Purification: 1. Resuspend the lyophilized beads by adding the buffer of choice. 2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein. 3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads. 4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.

    The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.

  • Formulation

    Please contact us for detailed information.

    Contact us for customized product form or formulation.

Typical Data
 VEGF165 TYPICAL DATA

Immobilized 31.6 μg VEGF165 protein/1mg beads can bind Anti-VEGF Antibody with an EC50 of 0.7726 μg/mL.

 VEGF165 TYPICAL DATA

Accelerated stability test. After placing the lyophilized beads at 37°C for 7 days, binding activity between the Human VEGF165-coupled Magnetic Beads (Cat.No. MBS-K036) and Bevacizumab showed little deviation from the unaccelerated sample (%RSD<10%). Data were measured on day 0, 3, 7 respectively.

 VEGF165 TYPICAL DATA

Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the Human VEGF165-coupled Magnetic Beads (Cat.No. MBS-K036) and Bevacizumab showed little deviation from the unfree-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.

  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €810.00

Price(EUR) : €2530.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:40 Details
  • Number of Drugs in Clinical Trials:63 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message